VIVUS (VVUS) has been under a strong bear grip, hence the stock is down -7.39% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 4.23% in the past 1 week. The stock has risen by 4.67% in the past week indicating that the buyers are active at lower levels, but the stock is down -5.08% in the past 4 weeks.
VIVUS (NASDAQ:VVUS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.10 and $1.08 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.13. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.12, notching a gain of 6.67% for the day. The total traded volume was 803,443 . The stock had closed at $1.05 on the previous day.
The stock has recorded a 20-day Moving Average of 0.81% and the 50-Day Moving Average is 3.05%. VIVUS Inc. has dropped 15.79% during the last 3-month period . Year-to-Date the stock performance stands at 9.8%.
VIVUS (VVUS) : The consensus price target for VIVUS (VVUS) is $1.9 for the short term with a standard deviation of $1.27. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $3, however, the pessimist price target for the company is $1.
VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.